The Dexcom 15-day G7 continuous glucose monitor (CGM) is currently under review by the US Food and Drug Administration and has shown promising accuracy and safety for use up to 15.5 days in adults with diabetes.

A multicenter study involving 130 adults, primarily with type 1 diabetes, assessed the performance of the 15-day G7 sensor across six clinical sites in the U.S.

Participants utilized the Dexcom G7 CGM device, with data analyzed from 20,310 matched readings comparing G7 glucose readings to venous blood analysis using the YSI 2300 Stat Plus glucose analyzer.

Dr. Satish Garg from the University of Colorado Denver reported that the device exceeded performance goals for integrated continuous glucose monitoring (iCGM) and received positive user feedback.

The study's findings were presented by Dr. Garg at the ATTD 2025 meeting on March 20, 2025, and subsequently published in Diabetes Technology and Therapeutics.

The investigators concluded that the Dexcom 15-day G7 CGM is accurate and safe for use for up to 15.5 days, requiring a 27-minute warm-up period.

This extended wear time and rapid warm-up period of 27 minutes is currently the lowest available in the market, potentially enhancing glucose management for diabetes patients.

The mean absolute relative difference (MARD) for the Dexcom G7 was calculated at 8.0%, marking the lowest MARD reported in a study designed according to the FDA's iCGM criteria.

This MARD of 8.0% indicates improved accuracy compared to the current 10-day G7 model, which has a MARD of 8.2%.

The sensor maintained high accuracy across various wear periods and patient demographics, with 87.7% to 99.8% of readings falling within specified accuracy thresholds for glucose levels.

Notably, no serious adverse events were reported during the study, underscoring a favorable safety profile for the device.

Of the 5019 hypoglycemia alerts triggered at a threshold of 70 mg/dL, 82.0% were confirmed as true alerts within 15 minutes by the YSI.